Oncologist’s Corner: Conversations With Cancer Experts About Novel Delivery Options With Immune Checkpoint Inhibitors

To participate in this activity, please:

Log in Sign Up

Immune checkpoint inhibitors (ICIs) have transformed the field of oncology across numerous tumor types over the last 10 to 15 years. Historically administered intravenously, ICIs may cause infusion-related reactions, require line access, and pose substantial staff and chair-time burdens. Recently, 2 ICIs (atezolizumab and nivolumab) were approved for subcutaneous administration, with additional ICIs in development. In this paired conversation activity, community oncologist Lucio Gordan, MD, and academic oncologist Saby George, MD, discuss the real-world burden related to ICI therapies administered intravenously and how subcutaneous formulations address these burdens. They also compare the clinical efficacy and safety profiles of subcutaneous and intravenous ICI products. The activity also highlights the importance and role of the interprofessional, multidisciplinary team in shared decision-making, treatment individualization, operationalization of subcutaneous ICIs, and workflow optimization.

This content is also available as a podcast. You may listen here.

Course Credit:

1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
1.00 Pharmacology Hour

Dates:

Opens: 2025-07-31
Closes: 2026-07-31

Target Audience:

This activity is intended for a national audience of community-based and hospital-based oncologists, urologists, dermatologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists.

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 1 pharmacology hour.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and Pharmacosmos


Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Christopher Flores, MD

    Family Medicine Physician
    Eisenhower Medical Center
    Rancho Mirage, California

  • Saby George, MD headshot

    Saby George, MD

    Professor of Medicine
    Roswell Park Comprehensive Cancer Center
    Director of Network Clinical Trails
    Roswell Park Comprehensive Cancer Center
    Tenured Professor of Medicine
    Jacobs School of Medicine
    University of Buffalo
    Buffalo, New York

  • Lucio Gordan, MD headshot

    Lucio Gordan, MD

    President and Managing Physician
    Florida Cancer Specialists & Research Institute
    Gainesville, Florida

  • LaTosha Mollette, DNP

    Family Nurse Practitioner
    Louisiana Family Medicine Clinic
    Jonesboro, Louisiana

  • Michael Smith, PharmD

    Clinical Pharmacist in Pain/Palliative Care
    University of Michigan
    Ann Arbor, Michigan

Learning Objectives

  • Compare the advantages and disadvantages of intravenous and subcutaneous routes of administration for immune checkpoint inhibitors across multiple tumor types.
  • Create individualized and evidence-based treatment approaches with innovative subcutaneous delivery methods for patients with cancer.
  • Develop strategies to improve the care provided to patients treated with immune-checkpoint inhibitor therapy by the interprofessional, multidisciplinary care team.

Faculty Disclosures

Christopher Flores, MD

No relationships to disclose.

Saby George, MD

Advisory Board: AstraZeneca, Aveo, Bayer, BMS, Corvus, Eisai, EMD Serono, Exelixis, Gilead, GSK, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Sanofi, Seattle Genetics

Consultant: Bayer, AstraZeneca, Aveo, BMS, Corvus, Eisai, EMD Serono, Exelixis, GSK, Gilead, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Seattle Genetics, Sanofi

Research Support: Aravive, Bayer, BMS, Calithera, Corvus, Exelixis, Gilead, Merck Sharp & Dohme, Novartis, Seattle Genetics, Surface Oncology


Lucio Gordan, MD

No relationships to disclose.

LaTosha Mollette, DNP

No relationships to disclose.

Michael Smith, PharmD

No relationships to disclose.